Q-omics provides the consensus-scored THRB profile across patient tissues and cancer cell-line models. THRB expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, THRB is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, THRB RNA expression shows 17,857 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where THRB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THRB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THRB survival associations across molecular data types. THRB RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THRB RNA expression–survival associations across cancer types. High THRB expression shows unfavorable associations in UCEC and LUAD, but favorable associations in KIRC, ACC, COAD and PRAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for THRB RNA expression.
This table summarizes THRB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for THRB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THRB shows lower tumor expression in KIRC, COAD, KIRP, THCA, READ and LUSC. The KIRC box plot shows higher THRB RNA expression in normal versus tumor tissue (log2 FC = −2.083, t-test p < 0.001).
This table shows molecular features associated with THRB in patient tissues and cancer cell lines. In patient samples, THRB shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, THRB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
